An evaluation of cabotegravir for HIV treatment and prevention

References

• Centers for Disease Control and Prevention (CDC). Advancing HIV prevention: new strategies for a changing epidemic–United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329–332.
   PubMedGoogle Scholar
• Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464:217–223.
   PubMed Web of Science ®Google Scholar
• Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–1983.
   PubMed Web of Science ®Google Scholar
• UNAIDS Science Panel. Making the end of AIDS real: consensus building around what we mean by “epidemic control. Geneva: UNAIDS; 2018. [updated 2019 Jul 4]. Available from: http://www.unaids.org/sites/default/files/media_asset/glion_oct2017_meeting_report_en.pdf
   Google Scholar
• D’Amico R, Margolis DA. Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection. Curr Opin HIV AIDS. 2020;15(1):13–18.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Tieu HV, Jones J, et al. CROI 2019: advances in antiretroviral therapy. Top Antivir Med. 2019;27:50–68.
   PubMedGoogle Scholar
• Anderson PL, Glidden DV, Liu A, iPrEx Study Team, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.
   PubMed Web of Science ®Google Scholar
• Montgomery ET, Atujuna M, Krogstad E, et al. The invisible product: preferences for sustained-release, long-acting pre-exposure prophylaxis to HIV among South African youth. J Acquir Immune Defic Syndr. 2019;80(5):542–550.
   PubMed Web of Science ®Google Scholar
• Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long-acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018;13:e0190487.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naïve persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2019;2019:ciz407.
   Google Scholar
• Landovitz RJ, Zangeneh SZ, Chau G, et al. cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70:319–322.
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Donnel D, Clement ME, et al. HPTN083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW). 23rd International HIV Conference (AIDS 2020: Virtual), abstract OAXLB0101; 2020.
   Google Scholar
• Karmon SL, Mohri H, Spreen W, et al. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J Acquir Immune Defic Syndr. 2015;68(3):e39–e41.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C. Pharmacokinetics and pharmacodynamics of cabotegravir, a long-acting HIV integrase strand transfer inhibitor. Eur J Drug Metab Pharmacokinet. 2019;44:319–327.
   PubMed Web of Science ®Google Scholar
• Orkin C, Arastéh K, Hernández-Mora Gorgolas M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.
   Google Scholar
• Swindells S, Andrade–Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020 Mar 19;382:1112–1123.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Zhao XZ, Burke TR, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15:37.
   PubMed Web of Science ®Google Scholar
• Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61:e01695–e016117.
   PubMed Web of Science ®Google Scholar
• Trezza C, Ford SL, Spreen W, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239–245.
   PubMed Web of Science ®Google Scholar
• Bowerman B, Brown PO, Bishop JM, et al. A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev. 1989;3:469–478.
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–650.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–708.
   PubMed Web of Science ®Google Scholar
• Yoshinaga T, Seki T, Miki S, et al. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res. 2018;152:1–9.
   PubMed Web of Science ®Google Scholar
• Saladini F, Giannini A, Boccuto A, et al. Comparable in vitro activities of second-generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations. Antimicrob Agents Chemother. 2019;64:e01717–e01719.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15:56.
   PubMed Web of Science ®Google Scholar
• Bowers GD, Culp A, Reese MJ, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46:147–162.
   PubMed Web of Science ®Google Scholar
• Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46(5):445–456.
   PubMed Web of Science ®Google Scholar
• Ford SL, Sutton K, Lou Y, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017;61(10):e00487–00517.
   PubMed Web of Science ®Google Scholar
• Jucker BM, Alsaid H, Rambo M, et al. Multimodal imaging approach to examine biodistribution kinetics of cabotegravir (GSK1265744) long acting parenteral formulation in rat. J Control Release. 2017;268:102–112.
   PubMed Web of Science ®Google Scholar
• Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14:192–203.
   PubMed Web of Science ®Google Scholar
• Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67:481–486.
   PubMed Web of Science ®Google Scholar
• Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67:487–492.
   PubMed Web of Science ®Google Scholar
• Rajoli RKR, Back DJ, Rannard S, et al. In silico dose prediction for long-acting rilpivirine and cabotegravir administration to children and adolescents. Clin Pharmacokinet. 2018;57:255–266.
   PubMed Web of Science ®Google Scholar
• Van der Galiën R, Ter Heine R, Greupink R, et al. Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps. Clin Pharmacokinet. 2019;58:309–323.
   PubMed Web of Science ®Google Scholar
• Ford S, Crauwels H, Han K, et al. Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation. Conference on Retroviruses and Opportunistic Infections (CROI); 2020 March 8–11; Boston, MA. Abstrct 466.
   Google Scholar
• Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145–1155.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez–Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
   PubMed Web of Science ®Google Scholar
• Overton ET, Richmond GJ, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study. Conference on Retroviruses and Opportunistic Infections (CROI); 2020 March 8–11; Boston, Massachusetts. Abstract 34.
   Google Scholar
• Margolis DA, Sutton KC, De Vente J, et al. Long-term efficacy, safety and durability of CAB and RPV as two drug oral maintenance therapy–LATTE week 312 results. IDWeek; 2019 Oct 2–6; Washington, DC, United States; Abstract 2840.
   Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Safety, efficacy and durability of long-acting CAB and RPV as two drug im maintenance therapy for HIV-1 infection: LATTE-2 week 160 results. HIV Drug Therapy; 2018 Oct 28–31,Glasgow, Scotland; Poster 118.
   Google Scholar
• Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results. Conference on Retroviruses and Opportunistic Infections (CROI); 2020 March 8–11; Boston, Massachusetts. Abstract 482.
   Google Scholar
• Llibre JM, Hung -C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 4(8): e331–e340. 2017.
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 15(11): e1002690. 2018.
   PubMed Web of Science ®Google Scholar
• Overton ET, Orkin C, Swindells S, et al. Monthly long-acting cabotegravir and rilpivirine is noninferior to oral ART as maintenance therapy for HIV-1 infection: week 48 pooled analysis from the phase 3 ATLAS and FLAIR studies. 10th IAS Conference on HIV Science; 2019 July 21–24; Mexico City, Mexico. MOPEB257.
   Google Scholar
• Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):19–26.
   PubMed Web of Science ®Google Scholar
• Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33(1):10–19.
   PubMed Web of Science ®Google Scholar
• Kandel CE, Walmsley SL. Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther. 2015;9:3547–3555.
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Castagna A, Lazzarin A. Bictegravir. Curr Opin HIV AIDS. 2018;13(4):326–333.
   PubMed Web of Science ®Google Scholar
• McPherson TD, Sobieszczyk ME, Markowitz M. Cabotegravir in the treatment and prevention of human immunodeficiency virus-1. Expert Opin Investig Drugs. 2018;27(4):413–420.
   PubMed Web of Science ®Google Scholar
• Sebaaly JC, Kelley D. Single-tablet regimens for the treatment of HIV-1 infection. Ann Pharmacother. 2017;51(4):332–344.
   PubMed Web of Science ®Google Scholar
• Masters MC, Krueger KM, Williams JL, et al. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol. 2019;12:1129–1143.
   PubMed Web of Science ®Google Scholar
• Currier JS. Monthly injectable antiretroviral therapy — version 1.0 of a new treatment approach. N Engl J Med. 2020;382(12):1164–1165.
   PubMed Web of Science ®Google Scholar
• McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.
   PubMed Web of Science ®Google Scholar
• Molina J-M, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–2246.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, Clarke A, Post FA, et al. Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis: week 96 results. 17th European AIDS Conference; 2019 Nov 6–9, Basel, Switzerland; Poster presentation PE3.16.
   Google Scholar
• Coelho LE, Torres TS, Veloso VG, et al. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019;6(11):e788–e799.
   PubMed Web of Science ®Google Scholar